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Abstract
Clonal hematopoiesis (CH) is a common aging-associated condition with increased risk of 
hematologic malignancy. Knowledge of the mechanisms driving evolution from CH to overt 
malignancy has been hampered by a lack of in vivo models that orthogonally activate mutant 
alleles. Here, we develop independently regulatable mutations in DNA methyltransferase 3A 
(Dnmt3a) and nucleophosmin 1 (Npm1), observed in human CH and AML respectively. We find 
Dnmt3a mutation expands hematopoietic stem and multipotent progenitor cells (HSC/MPPs), 
modeling CH. Induction of mutant Npm1 after development of Dnmt3a-mutant CH causes 
progression to myeloproliferative disorder (MPD), and more aggressive MPD is observed with 
longer latency between mutations. MPDs uniformly progress to acute myeloid leukemia (AML) 
following transplant, accompanied by a decrease in HSC/MPPs and an increase in myeloid-
restricted progenitors, the latter of which propagate AML in tertiary recipient mice. At a molecular 
level, progression of CH to MPD is accompanied by selection for mutations activating Ras/Raf/
MAPK signaling. Progression to AML is characterized by additional oncogenic signaling 
mutations (Ptpn11, Pik3r1, Flt3) and/or mutations in epigenetic regulators (Hdac1, Idh1, Arid1a). 
Together, our study demonstrates that Npm1 mutation drives evolution of Dnmt3a-mutant CH to 
AML and rate of disease progression is accelerated with longer latency of CH.
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Introduction
CH occurs when stem and progenitor cell clones gain one or more somatic mutations that 
confer a competitive advantage (1). This can be observed in patients by an increase in the 
variant allele frequency (VAF) of somatic mutations in the blood or bone marrow (BM) (2). 
There is a vast spectrum of outcomes in individuals with CH; in many cases, CH causes little 
to no clinically relevant hematopoietic phenotype. At the other extreme, CH cases represent 
a permissive state for development of BM failure syndromes including myelodysplastic 
syndrome (MDS) (3, 4), myeloproliferation including myeloproliferative disorder (MPD) (5) 
or leukemias including acute myeloid leukemia (AML), the last of which is accompanied by 
additional somatic mutations (6–8). Pressing clinical issues include how to identify 
individuals with CH for which this condition should be considered a medically important 
event and how to develop therapies that might prevent onset of hematologic malignancies. 
To answer these questions, we need to understand the factors (specific somatic mutations, 
genetic background of the individual, environmental factors, etc.) that cause evolution of CH 
to hematologic malignancies. A current barrier is the lack of available animal models that 
undergo the evolution of CH to hematologic malignancies in a native in vivo environment.
The most common somatic mutations present in CH are in genes associated with epigenetic 
modifications, including the DNA methyltransferase DNMT3A, and splicing factors. Several 
mouse models of DNMT3A-driven CH have been generated by conditional knockout (9), 
mutant allele knockin (10, 11) or mutant allele overexpression (12). Further, several studies 
have identified cooperating mutations that can act synergistically with Dnmt3a knockout or 
mutation to cause leukemia, such as Flt3ITD (13, 14), Flt3ITD and Npm1c (11), cKit (15), 
and KrasG12D (16). However, existing combinatorial mutation models are limited by the use 
of germline alleles with conditional alleles (thereby not modeling the known somatic nature 
of these mutations), multiple conditional alleles that are induced simultaneously by Cre 
recombination, or conditional alleles combined with ex vivo transduction/overexpression of 
cooperating mutations. Thus, based on the design of previous mouse models, none are able 
to evaluate the evolution of CH to hematologic malignancies within a native in vivo 
environment.
To overcome these limitations, we have developed an inducible, dual-recombinase system 
combining flippase-FRT (Flp-FRT) and Cre-loxP recombination technologies (17, 18) to 
improve genetically engineered mouse models of CH and to allow study of the evolution of 
CH to hematopoietic malignancy. This dual-recombinase system allows for sequential 
induction of a Dnmt3a hotspot mutation in R878H (Dnmt3aR878H), replicating human 
R882H (1), and the recurrent hotspot mutation in the multifunctional nuclear protein Npm1 
(Npm1c type A; Npm1cA) (19, 20). Previously, concurrent expression of Dnmt3aR878H and 
Npm1cA mutations was not found to cause a lethal malignancy within a 45-week observation 
period (11), however it remains unknown whether malignancy would have occurred over a 
longer timeframe or with a latency period between expression of these two mutations. 
Therefore, we have utilized our model to examine the cellular and molecular alterations 
during evolution of CH to hematologic malignancy within a native in vivo environment.
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Materials and Methods
Genetic Engineering of Dnmt3afl-R878H/+ and Npm1frt-cA/+ Mice
Targeting vectors mDnmt3a_LSL_exon23_bGHpA_pBlight and 
mNpm1_FS12_exon11_FSF_pBlight were generated by in vitro synthesis (GenScript). The 
Dnmt3afl-R878H/+ construct design placed wild-type exon 23 in a loxP-flanked STOP 
cassette (4xSV40pA) into the intron between exons 22 and 23, and the 3’ homology arm 
included the 2633G>A in exon 23 to encode the R878H mutation. The Npm1frt-cA/+ 
construct design placed wild-type exon 11 in an FRT-flanked STOP cassette (4xSV40pA) 
into the intron between exons 10 and 11, and the 3’ homology arm included a frameshift 
mutation to create a humanized mutant exon 11 (p.W288fs*12). Constructs were linearized 
and electroporated into C57BL/6 embryonic stem (ES) cells. Clones were screened by loss-
of-allele PCR, confirmed by Southern blot and microinjected into C57BL/6 blastocysts. 
PCR genotyping of pups was used to screen for germline transmission (primer sequences in 
Table S1).
Experimental Animals
C57BL/6J and B6.SJL-PtprcaPepcb/BoyJ (referred to as “B6.CD45.1”) mice were obtained 
from, and aged within, The Jackson Laboratory. Dnmt3afl-R878H/+ mice were crossed to 
B6.Cg-Tg(Mx1-cre)1Cgn/J mice (referred to as Mx1-cre) (21). Npm1frt-cA/+ mice were 
crossed to B6N.129S6(Cg)-Gt(ROSA)26Sortm3(CAG-flpo/ERT2)Alj/J (referred to as R26FlpoER) 
(22). Unless otherwise noted, all mice were female and experiments initiated at 8–16 weeks 
of age. Mice were injected five times (once every other day) via intraperitoneal (IP) injection 
with 15 mg/kg high molecular weight polyinosinic-polycytidylic acid (pIpC) (InvivoGen) to 
induce Mx1-Cre recombinase expression. Mice were administered 125 mg/kg tamoxifen 
three times (on consecutive days) via oral gavage to induce R26FlpoER recombinase 
expression. Before and after pIpC or tamoxifen administration, genomic DNA was extracted 
from PB cells for recombination PCR using primers specified above (Table S1). In addition, 
RNA was extracted and cDNA synthesized from whole BM cells for Sanger sequencing to 
verify mutant allele expression. Real-time PCR was utilized to examine relative expression 
of Dnmt3a in Dnmt3afl-R878H/+ Mx1-cre+ animals prior to pIpC injection (primer sequences 
in Table S1). To verify cellular localization of Npm1cA, spleens from Npm1cA/+ R26FlpoER 
or control Npm1+/+ R26FlpoER mice were fixed, paraffin embedded and sectioned for 
immunohistochemistry using a polyclonal antibody raised against human NPM1 (Cell 
Signaling Technology). The Jackson Laboratory’s Institutional Animal Care and Use 
Committee (IACUC) approved all experiments.
Primary Cell Isolation and Hematopoietic Stem/Progenitor Cell Phenotyping
Single cell suspensions of BM were prepared by filtering crushed, pooled femurs, tibiae and 
iliac crests from each mouse. BM mononuclear cells (MNCs) were isolated by Ficoll-Paque 
(GE Healthcare Life Sciences) density centrifugation and stained with a combination of 
fluorochrome-conjugated antibodies from eBioscience, BD Biosciences, or BioLegend: 
CD45.2 (clone 104), c-Kit (clone 2B8), Sca-1 (clone 108129), CD150 (clone TC15–
12F12.2), CD48 (clone HM48–1), FLT3 (Clone A2F10), CD34 (clone RAM34), FcγR 
(clone 2.4G2), mature lineage (Lin) marker mix (B220 (clone RA3–6B2), CD11b (clone 
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M1/70), CD4 (clone RM4–5), CD8a (clone 53–6.7), Ter-119 (clone TER-119), Gr-1 (clone 
RB6–8C5)) and the viability stain propidium iodide (PI). Stained cells were either analyzed 
or sorted using a FACSAria with Diva software (BD Biosciences) based on the following 
surface marker profiles: LSK (Lin− Sca-1+ c-Kit+), LT-HSC (Lin− Sca-1+ c-Kit+ Flt3− 
CD150+ CD48−), ST-HSC (Lin− Sca-1+ c-Kit+ Flt3− CD150− CD48−), MPP2 (Lin− Sca-1+ 
c-Kit+ Flt3− CD150+ CD48+), MPP3 (Lin− Sca-1+ c-Kit+ Flt3− CD150− CD48+), MPP4 
(Lin− Sca-1+ c-Kit+ Flt3+), myeloid-restricted progenitors (MyPro; Lin− Sca-1− c-Kit+), 
GMP (Lin− Sca-1− c-Kit+ CD150− CD34+ FcγR+), CMP (Lin− Sca-1− c-Kit+ CD150− 
CD34+ FcγRlo) and MEP (Lin− Sca-1− c-Kit+ CD150− CD34− FcγR−). All flow cytometry 
data was analyzed using FlowJo software.
Colony Formation Unit (CFU) Assay
De novo isolated cells were plated in MethoCult GF M3434 (StemCell Technologies) at the 
indicated numbers and cultured at 37oC and 5% CO2. Colonies were scored between 6–14 
days post-plating using a Nikon Eclipse TS100 inverted microscope. For CFU replating 
assay, colonies were harvested, total viable cell counts obtained, and then 5×104 cells were 
replated in MethoCult GF M3434. To examine allele recombination at the clonal level, 
whole BM was plated from Dnmt3aR878H/+ Npm1cA/+ mice with MDS/MPD or MPD 
phenotypes. Individual colonies were picked under a Nikon Eclipse microscope (4X 
magnification) and used for colony PCR to examine recombination of Dnmt3aR878H and 
Npm1cA alleles (primers listed in Table S1).
In Vivo Transplantation
For competitive transplantation, 2×106 BM MNCs from Dnmt3afl-R878H/+ Mx1-Cre or 
Dnmt3a+/+ Mx1-Cre mice were combined at a 1:1 ratio with 2×106 BM MNCs from 
B6.CD45.1 mice and intravenously injected into female recipient B6.CD45.1 mice that 
received a lethal dose of gamma irradiation (1200 rads, split dose). Recipient mice received 
pIpC injections as described at 5 weeks post-transplant. For non-competitive transplantation, 
106 BM MNCs from Dnmt3aR878H/+ Npm1cA/+ Mx1-Cre R26FlpoER or Dnmt3a+/+ Npm1+/+ 
Mx1-Cre R26FlpoER mice were intravenously injected into female recipient B6.CD45.1 mice 
that received a lethal dose of gamma irradiation (1200 rads, split dose). Recipient mice 
received pIpC injections as described at 4–5 weeks post-transplant, and tamoxifen 
administration at various times post-pIpC as indicated. Recipient mice were monitored every 
4 weeks thereafter by flow cytometry analysis of PB samples using a cocktail of CD45.1 
(clone A20), CD45.2, CD11b, B220, CD3ε (clone 145–2C11) and Gr-1 on an LSRII (BD). 
For secondary transplantation studies, female B6.CD45.1 mice received a sublethal dose of 
gamma irradiation (600 rads) and were intravenously injected with 106 BM MNCs from 
moribund primary recipients of Dnmt3aR878H/+ Npm1cA/+ Mx1-Cre R26FlpoER cells. For 
tertiary transplantation studies, female B6.CD45.1 mice received a sublethal dose of gamma 
irradiation (600 rads) and were intravenously injected with 5×103 sorted MyPro (Lin− 
Sca-1− c-Kit+) from moribund secondary recipients of Dnmt3aR878H/+ Npm1cA/+ Mx1-Cre 
R26FlpoER cells.
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Analysis of Moribund Mice
Mice demonstrating declining health status were sacrificed and PB, spleen, liver, and BM 
harvested. Differential blood cell counts were obtained from PB using an Advia 120 
Hematology Analyzer (Siemens). Single-cell suspensions of PB, spleen, and BM were 
analyzed by flow cytometry for mature lineage markers and c-Kit on an LSRII. Cytospin 
preparations of whole BM MNCs were stained with May-Grunwald-Giemsa stain. Liver and 
spleens were fixed for 24 h in 10% buffered formalin phosphate, embedded in paraffin, and 
sections were stained with H&E. Images of stained BM, liver, and spleen slides were 
captured on a Nikon Eclipse E200 upright microscope with SPOT imaging software (v.5.2).
M-IMPACT
Genomic DNA was extracted from isolated BM cells of diseased mice and WT littermates. 
DNA underwent targeted capture and deep sequencing performed by the MSKCC Integrated 
Genomics Operation Core using the MSK mouse Integrated Mutation Profiling of 
Actionable Cancer Targets (M-IMPACT) v1 assay. M-IMPACT is a DNA sequencing assay, 
which captures and sequences the exons and select introns of 578 known cancer genes, using 
solution-phase hybridization-based exon capture as described previously (23). Gene 
selection, mouse ortholog mapping, and bait design has been described previously (23, 24). 
Mouse genomic DNA (250ng) was used for library construction with molecular barcoding 
of each sample occurring prior to capture and sequencing. Equimolarly pooled libraries 
containing captured DNA fragments were subsequently sequenced on one lane of an 
Illumina HiSeq system for paired end 125/125 reads with intended 500X coverage for all 
reads. Sequencing analysis was performed by the MSKCC Bioinformatics Core. Processed 
FASTQ files were mapped to the mouse reference genome mm10 (GRCm38) using BWA-
MEM (Burrows-Wheeler Aligner v0.7.12; http://arxiv.org/abs/1303.3997). Resulting files 
were sorted, grouped, and PCR duplicates identified by MarkDuplicates in PICARD Tools 
(v1.124; https://github.com/broadinstitute/picard). BAM files were processed through GATK 
toolkit (v3.2) (25) to perform variant calling in tumor-vs-normal paired mode. Specifically, 
somatic single nucleotide variants (SNVs) were called from processed BAM files using 
muTect (v1.1.7) (26). Haplotype caller from GATK was used to identify somatic small 
insertions and deletions (indels) with a custom post-processing script (https://github.com/
soccin/Variant-PostProcess). Variant allele frequency (VAF) was determined by calculating 
the fraction of variant reads for a specific out of the total reads at that location.
Statistical Analysis
No sample group randomization or blinding was performed. For overall survival, Log-rank 
(Mantel-Cox) test was performed on Kaplan-Meier survival curves. Statistical analysis of 
non-survival data was performed by unpaired student’s t test, non-parametric one-way 
ANOVA (Kruskal-Wallis test) followed by Dunn’s multiple comparisons test, or two-way 
ANOVA followed by Tukey’s multiple comparisons test. For these experiments, a minimum 
of 3 samples per condition was chosen to detect statistical differences with >80% power at 
an error rate of 5%. All statistical tests, including evaluation of normal distribution of data 
and examination of variance between groups being statistically compared, were assessed 
using Prism 7 software (GraphPad).
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Results
Generation of an independently regulatable Dnmt3aR878H allele
To generate an inducible mouse model of human DNMT3A-mutant (DNMT3AR882H) CH, 
we engineered a Cre-inducible knockin model of the equivalent Dnmt3aR878H mutation in 
mice (Fig. 1A, Fig. S1A,B). While the general targeting strategy was similar to two recently 
published knockin models of Dnmt3aR878H (10, 11), our model has unique advantages of 
preserving expression of wild-type Dnmt3a prior to Mx1-Cre-mediated recombination (Fig. 
S1C) and following recombination, the Dnmt3aR878H mutant allele retains endogenous 
polyA and 3’ UTR elements. Indeed, prior to induction of Mx1-Cre by injection of poly(I:C) 
(pIpC), there is no observable change in frequency of the hematopoietic stem and progenitor 
cell compartment in the BM of Dnmt3afl-R878H mice (Fig. S1D). Furthermore, there is no 
observable change in frequency of stem and progenitor cell subsets including long-term 
HSCs (LTHSC), short-term HSCs (STHSC), multipotent progenitor cell 2 (MPP2), MPP3, 
and MPP4 in the BM of Dnmt3afl-R878H mice (Fig. S1E, gating strategy shown in Fig. S1F). 
Thus, our mice model somatic acquisition of Dnmt3a mutation as it is observed in human 
CH.
Dnmt3aR878H/+ expands the HSC and MPP compartments
As Dnmt3a mutation is considered to be an early event causing CH, we first investigated the 
phenotype of our Dnmt3aR878H/+ Mx1-Cre mice. At 6 months following activation of Cre 
recombinase expression, we observed a significant expansion of both the percentage and 
total number of viable LTHSC, STHSC, MPP3, and myeloid progenitors (MyPro) in 
Dnmt3aR878H/+ versus control Dnmt3a+/+ mice (Fig. 1B,C). To examine the clonogenic 
potential of Dnmt3aR878H/+ cells, we isolated whole BM cells from control and 
Dnmt3aR878H/+ mice for colony-forming unit (CFU) assays. We observed similar numbers 
of total CFU emerging from control and Dnmt3aR878H/+ mice (Fig. 1D). However, there was 
a significant expansion of multilineage, mixed granulocyte/erythroid/macrophage/
megakaryocyte (GEMM) colonies (Fig. 1E), consistent with an expansion of multipotent 
stem and progenitor cells in the BM. Together, this data is generally consistent with human 
data demonstrating that the HSC compartment is most dramatically altered by the 
Dnmt3aR882H somatic mutation (8) and existing mouse Dnmt3aR878H models demonstrating 
expansion of stem and progenitor cells (10, 11).
To test the competitive fitness of Dnmt3aR878H/+ LTHSCs, we examined their ability to 
competitively reconstitute the hematopoietic system of an irradiated host. We isolated BM 
cells from control and Dnmt3aR878H/+ mice that had not yet received pIpC and transplanted 
them at a 1:1 ratio with wild-type B6.CD45.1 BM cells into lethally irradiated congenic 
B6.CD45.1 recipient mice (Fig. 1F). At 5 weeks post-transplant, following initial homing 
and engraftment of transplanted LTHSCs, all recipients were administered pIpC to induce 
Mx1-Cre expression and followed by monthly peripheral blood (PB) flow cytometry 
analysis. We observed that the chimerism (% CD45.2+ cells) in the PB was significantly 
higher from Dnmt3aR878H/+ cells compared to control Dnmt3a+/+ cells (Fig. 1G), supporting 
a competitive advantage of Dnmt3aR878H/+ HSCs. To determine whether this chimerism was 
biased toward production of particular types of mature hematopoietic cells, we examined 
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myeloid (CD11b+), B cell (B220+) and T cell (CD3+) populations, and Gr-1+ and Gr-1− 
cells (within the myeloid fraction) of donor-derived CD45.2+ PB cells. We observed no 
differences in mature hematopoietic lineage composition between Dnmt3aR878H/+ and 
control Dnmt3a+/+ cells (Fig. 1H, I). In contrast, examination of chimerism within the 
hematopoietic stem and progenitor cell compartment of recipient mice revealed increased 
numbers of donor-derived LTHSC, STHSC, MPP3 and myeloid-restricted progenitors 
(MyPro) (Fig. 1J). As this result closely resembles the hematopoietic stem and progenitor 
cell expansion in non-transplanted mice (Fig. 1C), these data together indicate that this 
expansion is a cell-intrinsic effect of the Dnmt3aR878H/+mutation.
Generation of an independently regulatable Npm1cA allele
To develop an independently regulatable cooperating mutation that may synergize with 
Dnmt3aR878H to drive AML, we generated a Flp-inducible knockin mouse model of 
humanized Npm1cA (Fig. 2A, Fig. S2A–C). Mutations involving the NPM1 are found in 
one-third of all AML cases (20). NPM1 mutations (referred to as NPM1c) disrupt tryptophan 
residues and generate an additional nuclear export signal leading to aberrant localization of 
NPM1c in the cytoplasm (27). Our general targeting strategy was similar to a published 
knockin model of humanized Npm1flox-cA (28), however, our model has a unique advantage 
of being Flp recombinase-inducible by the use of FRT sites rather than loxP sites. This 
strategy allows for independent regulation of the Dnmt3a and Npm1 mutant alleles. We 
utilized a Rosa26-knockin tamoxifen-inducible FlpoER mouse strain (22) to induce 
expression of Npm1cA following administration of tamoxifen. To compare alterations in the 
hematopoietic stem and progenitor cell compartment driven by Npm1cA as a single mutation 
with the Dnmt3aR878H/+ phenotype, we examined the frequency and total number of stem 
and progenitor cells in Npm1cA/+ mice at 4 months post-tamoxifen injection. This revealed a 
significant decrease in frequency of LTHSC (Fig. 2B) as well as total numbers of LTHSC 
and STHSC (Fig. 2C) in Npm1cA/+ compared to Npm1+/+ control mice. To examine the 
clonogenic potential of Npm1cA/+ cells, we isolated whole BM cells from control and 
Npm1cA/+ mice at 4 months post-tamoxifen injection for CFU assays. We observed a 
significant increase in the total number of colonies formed (Fig. 2D) and expansion in both 
granulocyte (G) and granulocyte-macrophage (GM) colony types (Fig. 2E). This Npm1cA/+ 
in vitro phenotype is in contrast to the Dnmt3aR878H/+ BM, which demonstrated an 
expansion of the multi-lineage GEMM colony type (Fig. 1E). Lastly, as Npm1cA/+ has been 
demonstrated to cause myeloproliferation and AML with 30% penetrance late in life 
(median survival 617 days) (28), we examined mature hematopoietic cell lineage 
composition in the PB in our Npm1cA/+ mice at 4 months post-tamoxifen injection. We 
observed no alteration in frequency of mature hematopoietic lineages in Npm1cA/+ mice 
compared to controls (Fig. 2F, G), suggesting that at the time point at which we observe 
changes in the hematopoietic stem and progenitor cell compartment and clonogenicity of 
BM cells, there is no overt peripheral myeloproliferation.
Dnmt3aR878H/+ Npm1cA/+ mice develop a lethal myeloproliferative disorder
We then crossed the Npm1frt-cA/+ mice with the Dnmt3afl-R878H/+ Mx1-Cre model, to 
generate compound Dnmt3afl-R878H/+ Npm1frt-cA/+ Mx1-Cre R26FlpoER mice. We induced 
expression of the Dnmt3aR878H mutation first then followed this with induction of Npm1cA 
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expression three months later to allow development of CH in the interim period (Fig. 3A). 
We first examined the clonogenic potential of BM cells isolated from these Dnmt3aR878H/+ 
Npm1cA/+ mice. We observed a significant increase in total CFU from Dnmt3aR878H/+ 
Npm1cA/+ BM compared to control (Fig. 3B). Assessing colony morphology revealed a 
significant increase in granulocyte (G) and granulocyte-macrophage (GM) colony types 
(Fig. 3C). Serial replating of Dnmt3aR878H/+ Npm1cA/+ colonies revealed robust 
proliferative and clonogenic potential for at least 13 passages (Fig. 3D), suggesting 
unlimited in vitro self-renewal potential.
To determine whether this enhanced clonogenic potential was reflective of transformation, 
we transplanted BM from control Dnmt3a+/+ Npm1+/+, single mutant Npm1frt-cA/+ or 
double mutant Dnmt3afl-R878H/+ Npm1frt-cA/+ mice into lethally irradiated recipient mice, 
administered pIpC at 1-month post-transplant, tamoxifen at 3 months post-pIpC, and 
followed the natural life course of the recipients (Fig. 3E). Importantly, this experimental 
design restricted expression of Dnmt3aR878H and Npm1cA exclusively to the hematopoietic 
compartment. We observed that within a 440-day period, 100% of Dnmt3aR878H/+ 
Npm1cA/+ recipient mice died while only 29% of single mutant Npm1cA/+ recipient mice 
died (Fig. 3F). The phenotypes at the time of death comprised two major groups; 67% (6 out 
of 9) Dnmt3aR878H/+ Npm1cA/+ mice had mixed myelodysplastic syndrome and 
myeloproliferative disorder (MDS/MPD) while 33% (3 out of 9) Dnmt3aR878H/+ Npm1cA/+ 
mice and 29% (2 out of 7) single mutant Npm1cA/+ mice had MPD (Fig. 3G). The single 
mutant Npm1cA/+ mice developed MPD with survival times of ~7.5–8 months post-
tamoxifen, demonstrating that this mutation is capable of causing myeloproliferation beyond 
our original 4-month post-tamoxifen sampling (Fig. 2F).
An extensive characterization of Dnmt3aR878H/+ Npm1cA/+ MDS/MPD, Dnmt3aR878H/+ 
Npm1cA/+ MPD and single mutant Npm1cA/+ MPD was performed to contrast phenotypic 
similarities and differences. The Dnmt3aR878H/+ Npm1cA/+ MDS/MPD phenotype was 
characterized by erythroid and myeloid dysplasia (Fig. 3H), pancytopenia including 
significantly decreased white blood cell (WBC) (Fig. 3I), red blood cell (RBC) (Fig. 3J) and 
platelet (PLT) counts (Fig. 3K), increased PB myeloid cell production (Fig. S3A), and 
myeloid cell infiltration into the spleen and liver (Fig. S3C,E). The Dnmt3aR878H/+ 
Npm1cA/+ MPD phenotype was characterized by significantly increased WBC count (Fig. 
3I), significantly decreased RBC and PLT counts (Fig. 3J,K), significantly increased spleen 
weight (Fig. S3D), increased PB myeloid cell production with monocyte bias (Fig. S3A,B), 
and myeloid (monocyte) cell infiltration into the spleen and liver (Fig. S3C–F). The single 
mutant Npm1cA/+ MPD phenotype was distinguished from Dnmt3aR878H/+ Npm1cA/+ MPD 
phenotype by lower WBC count (Fig. 3I), lower spleen weight (Fig. S3D) and greater 
monocyte bias in myeloid PB cells (Fig. S3B). Together, these data demonstrate that 
acquiring the Npm1cA mutation on pre-existing Dnmt3aR878H/+ CH causes progression to 
MDS/MPD or MPD.
To demonstrate one application of independently regulatable disease alleles, we examined 
whether the duration of pre-existing Dnmt3aR878H/+ CH would impact disease development 
or survival of mice. Npm1cA/+ was induced at 3, 10, 32, or 57 weeks post-recombination of 
Dnmt3aR878H/+ (Fig. 3L). We observed that longer latency between acquisition of Dnmt3a 
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and Npm1 mutations resulted in a significantly shorter survival time post-tamoxifen (3wks 
vs. 10wks, P = 0.067; 3 wks vs. 32 wks, ***P = 0.0009; 3wks vs. 57wks, ***P < 0.0001) 
(Fig. 3M). This suggests that a greater length of time with Dnmt3a-mutant clonal expansion 
increases the risk of progression to malignancy.
Dnmt3aR878H/+ Npm1cA/+ MPD progresses to AML upon transplant
While human NPM1 mutations are most often observed in de novo AML, several studies 
have shown that NPM1 mutations can be present in MDS or MDS/myeloproliferative 
neoplasm (MPN) prior to blast counts reaching the threshold for AML diagnosis (29, 30). 
This suggests Dnmt3aR878H/+ Npm1cA/+ MDS/MPD or MPD might have potential for 
further progression to AML. To determine whether Dnmt3aR878H/+ Npm1cA/+ MPDs were 
transplantable to recipient mice and to test whether they are capable of further progression to 
AML, we isolated BM cells from primary Dnmt3aR878H/+ Npm1cA/+ transplant recipients 
with either the MDS/MPD or MPD phenotypes and transplanted these cells into sublethally 
irradiated secondary recipient mice (Fig. 4A). We assessed donor cell engraftment (% 
CD45.2+) at 4 weeks post-transplant as well as when these mice were moribund. This 
analysis revealed that MPD samples achieved high levels of engraftment in secondary 
recipients almost immediately post-transplant (Fig. 4B). In contrast, MDS/MPD samples had 
initially low levels of engraftment in secondary recipients but dramatically expanded to 
achieve high levels of engraftment at the time of sacrifice. There was a significant difference 
between the survival of mice transplanted with MDS/MPD donors (median survival 188 
days) versus MPD donors (median survival 36 days) (Fig. 4C). However, these both 
represent a dramatic disease acceleration compared to the primary recipient animals (Fig. 
3F).
We observed that 100% of secondary transplant recipient mice succumbed to acute myeloid 
leukemia (AML), regardless of whether they were derived from an MDS/MPD or MPD 
primary donor. All Dnmt3aR878H/+ Npm1cA/+ recipients showed significantly increased 
WBC count and decreased RBC and PLT counts (Fig. 4D), increased spleen weight (Fig. 
4E), complete myeloid cell dominance in the PB with monocyte bias (Fig. 4F, G), >20% 
blast cells in the BM and vast infiltration of blast cells in the spleen and liver (Fig. 4H). 
Together these data suggest that Dnmt3aR878H/+ Npm1cA/+ MDS/MPD and MPD can both 
progress to AML.
To examine clonality of recombination of Dnmt3afl-R878H and Npm1frt-cA alleles in mice 
with MDS/MPD, MPD and AML, we performed a BM CFU assay and picked individual 
colonies for PCR. We observed that in MDS/MPD, 82% of colonies had recombination of 
both Dnmt3aR878H and Npm1cA (Fig. S3G). In MPD and AML, 100% of colonies had 
recombination of both Dnmt3aR878H and Npm1cA. This demonstrates similar levels of 
recombination in Dnmt3aR878H/+ Npm1cA/+ MDS/MPD, MPD and AML. To further 
examine additional acquired somatic mutations, we performed somatic mutational analysis 
of BM from MDS/MPD, MPD and AML samples using a custom targeted sequencing panel 
querying 578 known cancer genes (MSK-Mouse IMPACT; M-IMPACT) (Table S2). We 
observed that Dnmt3aR878H/+ Npm1cA/+ MDS/MPD was associated with mutations in the 
tumor suppressor Cux1, previously shown to drive MDS and MDS/MPD (31) and in the 
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RNA splicing genes Rbm10 and U2af2 (Fig. 4I, Table S3). Mutations in key factors of the 
spliceosome are known to occur frequently in CH and MDS (32). Development of 
Dnmt3aR878H/+ Npm1cA/+ MPD was associated with mutations activating the Ras/Raf/
MAPK pathway (including Nf1, Nras, Kras and Braf) at high VAF, consistent with known 
function of these mutations (33, 34). Progression to Dnmt3aR878H/+ Npm1cA/+ AML was 
also associated with these same mutations, but with the addition of mutations activating the 
tyrosine phosphatase SHP2 (Ptpn11), PI3K (Pik3r1) or Flt3 (Flt3) signaling as well as 
mutations involved in epigenetic regulation including Brd4, Hdac1, Idh1, and Arid1a. Many 
of these genes are recurrently mutated in human AML (35–37), and demonstrate additional 
mutations are required to cooperate with mutant Dnmt3a and Npm1 to promote 
transformation to MDS/MPD, MPD and AML.
Dnmt3aR878H/+ Npm1cA/+ AML mice have decreased HSC and increased myeloid 
progenitors
To determine how Dnmt3aR878H/+ CH progresses to MPD and AML with acquisition of 
Npm1cA mutation, we examined the BM stem and progenitor cell compartment of primary 
and secondary recipient mice transplanted with Dnmt3aR878H/+ Npm1cA/+ cells 
(representative gating shown in Fig. 5A). We observed a significant increase in LTHSC 
frequency in the Dnmt3aR878H/+ Npm1cA/+ MDS/MPD group and decrease in LTHSC 
frequency in the Dnmt3aR878H/+ Npm1cA/+ AML group compared to control transplanted 
mice (Fig. 5B). In addition, we observed a significant decrease in STHSC frequency in the 
Dnmt3aR878H/+ Npm1cA/+ MPD and AML groups compared to control transplanted mice. 
Strikingly, we observed that granulocyte-macrophage progenitors (GMP) were significantly 
expanded in the Dnmt3aR878H/+ Npm1cA/+ MPD and AML groups versus the control group 
(Fig. 5C). Together, these data suggest that Npm1cA transformation of Dnmt3aR878H/+ CH is 
accompanied by a shift in the stem and progenitor cell compartment towards expansion of 
myeloid-restricted progenitor cells at the expense of HSCs.
Dnmt3aR878H/+ Npm1cA/+ AML is propagated by myeloid-restricted progenitors
Within Dnmt3aR878H/+ Npm1cA/+ AML, the shift in the stem and progenitor cell 
compartment towards expansion of myeloid-restricted progenitor cells suggests that these 
cells may represent tumor-propagating cells capable of transferring disease to recipient mice. 
To test this, we performed a tertiary transplant of sorted myeloid progenitors (Lin− c-Kit+ 
Sca-1−) (Fig. 6A). We observed that 100% of tertiary transplant recipient mice succumbed to 
acute myeloid leukemia (AML) with a median survival of 56 days (Fig. 6B), similar to the 
rate and penetrance of AML development in secondary transplant recipients (Fig. 4C). This 
is evidenced in all recipients by significantly increased WBC and decreased PLT (Fig. 6C) 
counts, increased spleen weight (Fig. 6D), >20% blast cells in the BM and vast infiltration of 
blast cells in the spleen and liver (Fig. 6E). Together, these data support diagnosis of AML in 
secondary recipient animals and demonstrate that myeloid-restricted progenitors are 
leukemia stem cells (LSCs) capable of propagating Dnmt3aR878H/+ Npm1cA/+ AML.
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Discussion
Individuals with CH have an increased risk of development of hematologic malignancy, 
including AML. Currently, no methods exist to distinguish individuals with benign CH from 
those with pre-malignant CH due to a lack of understanding of the mechanisms by which 
CH progresses to AML. Improved in vivo models of the progression of CH to AML are 
needed to identify specific pathways and molecules for development of prognostic tests and 
therapies to prevent progression to malignancy. In this study, we have developed novel 
inducible mouse models allowing temporal control of expression of Dnmt3aR878H, a 
common event in human CH, and Npm1cA, a common cooperating mutation in human 
AML. We find that acquisition of Npm1cA/+ mutation on the background of pre-existing 
Dnmt3aR878H/+ CH drives development of MPD, which is transformed to AML upon 
subsequent transplantation. Furthermore, increasing the duration of Dnmt3aR878H/+ CH 
increased the aggressiveness of MPD development upon acquisition of Npm1cA/+ mutation 
and decreased overall survival in mice. Previously, the combination of Dnmt3aR878H/+ and 
Npm1cA/+ induced simultaneously did not cause lethal hematologic malignancy within a 45-
week timeframe (11). We hypothesize that this is distinct from our current findings based on 
the timeframe of the observation period of animals and the sequential acquisition of 
mutations over time with concomitant genetic and epigenetic evolution. Based on our 
results, we propose that accumulation of cellular and molecular alterations over time, as a 
consequence of Dnmt3a mutation, synergize with Npm1 mutation to cause more aggressive 
malignancy. These data are pertinent for considering the timing and importance of follow-up 
mutational screening in individuals with CH.
In our CH model, we find that heterozygous Dnmt3aR878H alone is sufficient to cause 
expansion of phenotypic and functional HSCs and MPPs, and confer a competitive 
advantage of LTHSCs over wild-type LTHSCs in vivo. Integrating this phenotype with 
published models of Dnmt3a knockout, which demonstrate specific expansion of LTHSCs 
(9), or Dnmt3aR878H mutation, which demonstrate expansion in both multipotent and 
myeloid progenitors downstream of the LTHSC (10, 11), suggest that the Dnmt3aR878H 
mutation is distinct from Dnmt3a loss. Dnmt3aR878H can confer impaired differentiation but 
not the complete differentiation block that is observed upon Dnmt3a loss (16), and 
Dnmt3aR878H HSCs, unlike Dnmt3a−/− HSCs (9, 16), do not appear to have overt lineage 
bias in the context of competitive transplantation.
In experiments examining the hematopoietic stem and progenitor cell compartment at 
different stages along the trajectory of CH to MPD and finally to AML, we revealed that 
Npm1cA/+ drives progressive transition of expansion of the HSC and MPP compartments in 
CH to the myeloid-restricted progenitor cell compartment in AML. Furthermore, these 
myeloid-restricted progenitor cells represent LSCs capable of propagating AML in 
transplanted recipient mice. Seminal work examining the pre-leukemic state in AML has 
suggested that the cell of origin acquiring DNMT3A mutation is an HSC, which causes an 
expanded pool of HSCs and downstream progenitors, within which additional mutations 
including NPM1c are acquired to drive progression to AML (8). These findings pointed to 
GMPs and/or mixed lineage progenitors (MLP) as the likely populations in which NPM1c 
was acquired. This model is consistent with our findings that progression of Dnmt3a-mutant 
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CH to Dnmt3a- and Npm1-mutant AML is accompanied by a depletion of the expanded 
pool of HSCs observed in CH and a shift towards an expanded pool of myeloid-restricted 
progenitors that possess LSC activity. These data also provide important context for 
interpretation of a previously published report demonstrating that conditional knockin of 
Dnmt3aR878H initiates AML in the absence of other engineered mutations after a long 
latency (10). This study found that LTHSCs decreased and myeloid lineage-restricted 
progenitors were expanded in their Dnmt3a-mutant AML mice. Based on these data taken 
together, we propose that a decline in HSC frequency and shift toward myeloid-restricted 
progenitor expansion in the HSPC compartment may serve as a biomarker for risk or early 
progression of CH to AML. Our data suggest that distinct cooperating mutations, in addition 
to Npm1, drive progression of Dnmt3a-mutant CH to MDS/MPD, MPD and AML. 
Mutations in the tumor suppressor Cux1 and RNA splicing factor mutations are associated 
with MDS/MPD, while strong selection for mutations activating Ras/Raf/MAPK signaling 
are invariably associated with progression to MPD. Furthermore, transformation to AML is 
accompanied by selection for additional mutations in signaling molecules and/or epigenetic 
regulatory factors.
Mutations in DNMT3A are common in the general population and increase with aging. With 
next-generation sequencing becoming more and more routine as a part of general medical 
care, we need better predictive tools to assess who is at risk for progression from CH to 
MDS, MPN or AML in addition to development of new preventative therapeutic strategies. 
Addressing a number of these pressing basic and translational research questions regarding 
the evolution of CH to AML will now be possible by utilizing the in vivo models we have 
developed. For example, different stressors and environmental factors (age, tobacco use, 
prior radiation therapy) have been hypothesized to facilitate emergence of clinically relevant 
phenotypes of the DNMT3A mutation (38). Our models will not only permit prospective 
testing of the effects of stress or environmental factors on the Dnmt3a-mutant CH 
phenotype, but also whether effects on CH ultimately change the risk of progression to 
malignancy upon acquisition of a cooperating mutation in Npm1. Furthermore, orthogonal 
regulation of the Dnmt3a and Npm1 mutations will permit interrogation of the underlying 
biological mechanisms by which these mutations interact to cause malignancy, including 
hematopoietic cell-intrinsic interactions (ex. chromatin regulation, DNA repair) and cell-
extrinsic interactions (ex. alterations in the BM cytokine environment). Lastly, this study 
serves as a proof-of-principle that utilizing an inducible, dual-recombinase system is a 
feasible and translationally relevant strategy to model combinations of somatic mutations in 
CH, pre-leukemia and hematologic malignancy and to model clonal evolution more broadly 
in different malignant contexts.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. Dnmt3aR878H/+ expands HSCs and multipotent progenitor cells.
(A) Schematic diagram of the design of the Dnmt3afl-R878H/+ allele. * indicates 2633G>A in 
exon 23 to encode the R878H mutation. (B) Frequency and (C) Total number of LTHSC, 
STHSC, MPP2, MPP3, MPP4 and MyPro cells in the BM of +/+ (n = 4) and R878H/+ (n = 
6) mice at 6 months post-pIpC. (D) Total colony-forming units (CFU) and (E) Colony types 
derived from 50K BM MNCs isolated from +/+ (n = 6) and R878H/+ (n = 8) mice at 4 
months post-pIpC. G (granulocyte), M (macrophage), GM (granulocyte-macrophage), 
BFUE (burst forming-unit erythroid), GEMM (mixed granulocyte-erythroid-macrophage-
megakaryocyte). Results are from 3 independent experiments. (F) Experimental design for 
competitive transplantation of +/+ or fl-R878H/+ BM cells with wild-type B6.CD45.1 BM 
cells at a 1:1 ratio into lethally irradiated B6.CD45.1 recipient mice followed by pIpC to 
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induce recombination of Dnmt3afl-R878H. (G) Frequency of donor-derived (CD45.2+) +/+ (n 
= 9) or R878H/+ (n = 9) cells in PB of recipient mice post-pIpC. Results are from 2 
independent experiments. (H) Frequency of myeloid (CD11b+), B (B220+) and T (CD3+) 
cells within donor-derived (CD45.2+) PB and (I) Gr-1+ and Gr-1− cells within donor-derived 
myeloid PB at 6 months post-pIpC. (J) Frequency of LTHSC, STHSC, MPP2, MPP3 and 
MyPro cells within donor-derived +/+ (n = 5) or R878H/+ (n = 5) BM at 6 months post-
pIpC. Results are from 2 independent experiments. In all graphs, dots represent individual 
mice, bars indicate mean ± s.e.m. *P < 0.05; **P < 0.01; ***P < 0.001.
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Figure 2. Npm1cA/+ depletes HSCs and expands myeloid colony-forming cells.
(A) Schematic diagram of the design of the Npm1frt-cA/+ allele. * indicates frameshift 
mutation to create a humanized mutant exon 12 (p.W288fs*12). (B) Frequency and (C) 
Total number of LTHSC, STHSC, MPP2, MPP3, MPP4 and MyPro cells in the BM of +/+ 
(n = 5) and cA/+ (n = 5) mice at 4 months post-tamoxifen. (D) Total CFU and (E) Colony 
types derived from 50K BM MNCs isolated from +/+ (n = 8) and cA/+ (n = 8) mice at 4 
months post-tamoxifen. Results are from 4 independent experiments. (F) Frequency of 
myeloid, B and T cells within PB and (G) Gr-1+ and Gr-1− cells within myeloid PB at 4 
months post-tamoxifen in +/+ (n = 6) and cA/+ (n = 12) mice. In all graphs, dots represent 
individual mice, bars indicate mean ± s.e.m. *P < 0.05; ***P < 0.001.
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Figure 3. Dnmt3aR878H/+ followed by Npm1cA/+ causes development of lethal MPD.
(A) Experimental design for induction of Dnmt3aR878H/+ driving clonal hematopoietic 
expansion prior to induction of Npm1cA/+, followed by in vitro CFU assay. (B) Total CFU 
and (C) Colony types derived from 50K BM MNCs isolated from control (n = 4) or 
R878H/+ cA/+ (n = 8) mice at 3 months post-tamoxifen. Results are from 3 independent 
experiments. (D) CFU derived from 50K BM MNCs isolated from control (n = 2) and 
R878H/+ cA/+ (n = 4) mice, serially passaged for up to 13 passages. Results are from 2 
independent experiments. (E) Experimental design for non-competitive transplantation of fl-
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R878H/+ frt-cA/+ BM into lethally irradiated recipient mice, followed by pIpC induction of 
R878H/+ and clonal hematopoietic expansion prior to tamoxifen induction of cA/+. (F) 
Overall survival of mice transplanted with 106 BM cells from control (n = 3), cA/+ only (n = 
7) or R878H/+ cA/+ (n = 13) mice. Results are from 3 independent experiments. (G) 
Description and penetrance of phenotypes in moribund mice following transplant with cA/+ 
only or R878H/+ cA/+ BM cells. (H) Representative Giemsa-stained BM cytospins (100X) 
from R878H/+ cA/+ MDS/MPD showing dysplastic cells (arrows). Scale bars are 10μm. (I) 
WBC count, (J) RBC count and (K) PLT count in moribund mice (control, n = 3; cA/+ 
MPD, n = 2; R878H/+ cA/+ MDS/MPD, n = 6; R878H/+ cA/+ MPD, n = 3). (L) 
Experimental design for tamoxifen induction of cA/+ at various times following induction of 
R878H/+. (M) Overall survival of mice transplanted with 106 BM cells with latency 
between R878H/+ and cA/+ mutations of 3 weeks (n = 10), 10 weeks (n = 11), 32 weeks (n 
= 3) or 57 weeks (n = 5). Results are from 3 independent experiments. In all graphs, dots 
represent individual mice, bars indicate mean ± s.e.m. *P < 0.05; **P < 0.01; ***P < 0.001.
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Figure 4. Dnmt3aR878H/+ Npm1cA/+ MPD progresses to AML following transplantation.
(A) Experimental design for non-competitive secondary transplantation of Dnmt3aR878H/+ 
Npm1cA/+ BM MNCs from primary recipient mice with MDS/MPD or MPD phenotypes. 
(B) Frequency of donor-derived (CD45.2+) cells in PB of secondary recipient mice at 4 wks 
post-transplant and at time of sacrifice. Dots represent mean ± s.e.m. (MPD, n = 7; MDS/
MPD, n = 3). Results are from 3 independent experiments. (C) Overall survival of secondary 
transplant recipient mice (MPD, n = 7; MDS/MPD, n = 3). (D) WBC, RBC and PLT counts 
and (E) Spleen weights of moribund mice (control, n = 4; +/+ cA/+, n = 10). (F) Frequency 
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of myeloid, B and T cells within the donor-derived CD45.2+ fraction in PB and (G) Gr-1+ 
and Gr-1− cells within donor-derived myeloid PB of moribund mice (control, n = 3; +/+ 
cA/+, n = 10). (H) Representative Giemsa-stained BM cytospins (far left; 40X, scale bars are 
40μm) and H&E-stained spleen (center; 4X, scale bars are 100μm) (inset: 40X, scale bars 
are 40μm) and liver sections (far right; 4X, scale bars are 100μm) from moribund recipient 
mice. (I) Somatic, nonsynonymous mutations in individual genes and sets of genes, grouped 
into five categories. Orange boxes indicate mutations at VAF 0.10–0.39; green boxes, VAF 
0.40–0.59; blue boxes, VAF 0.60–0.97. In all graphs unless otherwise specified, dots 
represent individual mice, bars indicate mean ± s.e.m. *P < 0.05; **P < 0.01; ***P < 0.001.
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Figure 5. Mice with Dnmt3aR878H/+ Npm1cA/+ AML show expansion of granulocyte-macrophage 
progenitor cells.
(A) Representative flow cytometric gating for hematopoietic stem and progenitor cells in 
recipient mice transplanted with Dnmt3a+/+ Npm1+/+ or Dnmt3aR878H/+ Npm1cA/+ with 
MDS/MPD, MPD or AML phenotypes. (B) Frequency of LTHSC, STHSC, MPP2 and 
MPP3 and (C) GMP, CMP and MEP in donor-derived CD45.2+ BM cells (control, n = 2; 
R878H/+ cA/+ MDS/MPD, n = 2; R878H/+ cA/+ MPD, n = 3; R878H/+ cA/+ AML, n = 4). 
Results are from 2 independent experiments.
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Figure 6. Myeloid-restricted progenitor cells are tumor-propagating cells in Dnmt3aR878H/+ 
Npm1cA/+ AML.
(A) Experimental design for non-competitive tertiary transplantation of FACS-sorted 
Dnmt3aR878H/+ Npm1cA/+ BM myeloid progenitors from secondary recipient mice with 
AML. (B) Overall survival of tertiary transplant recipient mice (n = 12). Results are from 3 
independent experiments. (C) WBC, RBC and PLT counts in moribund mice (control, n = 3; 
+/+ cA/+, n = 9). (D) Spleen weights of moribund mice (control, n = 3; +/+ cA/+, n = 11). 
(E) Representative Giemsa-stained BM cytospin (far left; 40X, scale bars are 40μm) and 
H&E-stained spleen (center; 10X, scale bars are 100μm) and liver sections (far right; 10X, 
scale bars are 100μm) from moribund recipient mice. In all graphs, dots represent individual 
mice, bars indicate mean ± s.e.m. **P < 0.01.
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